







































Volume 04 Issue 04-2024 1 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 04 PAGES: 1-7 

SJIF IMPACT FACTOR (2022: 5. 705) (2023: 6.534) (2024: 7.7) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

 

 

 

 

 

 

ABSTRACT 

Schizophrenia is a complex psychiatric disorder characterized by a range of cognitive, emotional, and behavioral 

symptoms. Despite significant advancements in pharmacotherapy, challenges such as poor treatment adherence, 

limited efficacy, and adverse side effects remain prevalent. Drug delivery systems have emerged as promising 

approaches to overcome these challenges by improving drug targeting, bioavailability, and patient compliance. This 

review explores recent advancements in drug delivery systems tailored for the targeted treatment of schizophrenia. 

Various strategies, including nanoparticle-based formulations, lipid-based carriers, depot injections, and transdermal 

patches, are examined for their potential to enhance the delivery of antipsychotic medications to the brain while 

minimizing systemic side effects. Additionally, the review discusses the application of novel technologies, such as 

implantable devices and nanoscale drug carriers, in optimizing drug release kinetics and achieving sustained 

therapeutic effects. By highlighting recent developments and future prospects in drug delivery for schizophrenia 

treatment, this review aims to inform researchers, clinicians, and pharmaceutical developers about the evolving 

landscape of targeted therapy in mental health care. 

KEYWORDS 

Schizophrenia, Drug delivery systems, Nanoparticles, Lipid-based carriers, Depot injections, Transdermal patches, 

Implantable devices, Targeted therapy, Antipsychotic medications. 

  Research Article 

 

TARGETED THERAPY: ADVANCEMENTS IN DRUG DELIVERY SYSTEMS 

FOR SCHIZOPHRENIA TREATMENT 
 

Submission Date: March 22, 2024, Accepted Date:  March 27, 2024,  

Published Date: April 01, 2024  

Crossref doi: https://doi.org/10.37547/ajbspi/Volume04Issue04-01 

 

 

Rajpal Yadav 
Department of Pharmaceutics, Institute of Pharmacy, Bundelkhand University Jhansi, Uttar Pradesh India 

 

Journal Website: 

https://theusajournals.

com/index.php/ajbspi 

Copyright: Original 

content from this work 

may be used under the 

terms of the creative 

commons attributes 

4.0 licence. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=
https://theusajournals.com/
https://doi.org/10.37547/ajbspi/Volume04Issue04-01
https://doi.org/10.37547/ajbspi/Volume04Issue04-01
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi


Volume 04 Issue 04-2024 2 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 04 PAGES: 1-7 

SJIF IMPACT FACTOR (2022: 5. 705) (2023: 6.534) (2024: 7.7) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

INTRODUCTION

Schizophrenia is a chronic and debilitating psychiatric 

disorder characterized by a range of symptoms, 

including hallucinations, delusions, disorganized 

thinking, and impaired cognitive function. 

Pharmacotherapy with antipsychotic medications is 

the cornerstone of treatment for schizophrenia, 

aiming to alleviate symptoms and improve patients' 

quality of life. However, despite the availability of 

various antipsychotic drugs, significant challenges 

persist in achieving optimal therapeutic outcomes. 

One of the foremost challenges in schizophrenia 

treatment is the limited efficacy and tolerability of 

existing pharmacological interventions. Many patients 

experience only partial symptom relief or inadequate 

response to medication, leading to persistent 

functional impairment and decreased quality of life. 

Furthermore, the management of schizophrenia is 

often complicated by poor treatment adherence, 

which can result from factors such as medication side 

effects, stigma, and lack of insight into the illness. 

In recent years, drug delivery systems have emerged as 

promising strategies to address the limitations of 

traditional oral medications in schizophrenia 

treatment. These systems offer the potential to 

enhance drug targeting, improve bioavailability, and 

optimize therapeutic efficacy while minimizing adverse 

effects and improving patient adherence. By 

harnessing innovative technologies and formulations, 

drug delivery systems aim to deliver antipsychotic 

medications more effectively to the brain, where they 

exert their therapeutic effects. 

This review explores the latest advancements in drug 

delivery systems tailored for the targeted treatment of 

schizophrenia. We will examine various strategies, 

including nanoparticle-based formulations, lipid-based 

carriers, depot injections, transdermal patches, 

implantable devices, and nanoscale drug carriers. 

Through a comprehensive analysis of recent research 

findings and emerging technologies, we aim to provide 

insights into the evolving landscape of targeted 

therapy in schizophrenia treatment. 

By elucidating the potential benefits and challenges of 

different drug delivery approaches, this review seeks 

to inform researchers, clinicians, and pharmaceutical 

developers about the opportunities for innovation in 

schizophrenia treatment. Ultimately, the goal is to 

pave the way for the development of more effective 

and patient-friendly treatment options that can 

improve outcomes and enhance the lives of individuals 

living with schizophrenia. 

METHOD 

In exploring the advancements in drug delivery 

systems for schizophrenia treatment, a systematic 

process was undertaken. Initially, a thorough literature 

search was conducted across various electronic 

databases, including PubMed, Scopus, and Web of 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 04-2024 3 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 04 PAGES: 1-7 

SJIF IMPACT FACTOR (2022: 5. 705) (2023: 6.534) (2024: 7.7) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Science, using relevant keywords pertaining to 

schizophrenia, drug delivery systems, and targeted 

therapy. This search yielded a comprehensive 

collection of articles encompassing both preclinical 

and clinical studies published within the past decade. 

Following the literature search, rigorous screening 

criteria were applied to select articles specifically 

focused on drug delivery systems tailored for 

schizophrenia treatment. These included nanoparticle-

based formulations, lipid-based carriers, depot 

injections, transdermal patches, implantable devices, 

and nanoscale drug carriers. Data extraction was then 

performed to gather information on formulation 

characteristics, pharmacokinetics, pharmacodynamics, 

efficacy, and safety profiles of the various drug delivery 

systems. 

Furthermore, a critical analysis was conducted to 

evaluate the comparative effectiveness and tolerability 

of different drug delivery approaches in schizophrenia 

treatment. This involved assessing the extent to which 

each system addressed the unique challenges 

associated with schizophrenia pharmacotherapy, such 

as poor oral bioavailability, blood-brain barrier 

penetration, and medication non-adherence. 

 

 

Throughout this process, insights from pharmacology, 

pharmaceutics, neuroscience, and clinical psychiatry 

were synthesized to provide a comprehensive 

overview of the advancements in drug delivery 

systems for schizophrenia treatment. Special attention 

was given to emerging technologies and novel 

formulations that hold promise for improving 

therapeutic outcomes and patient adherence in 

schizophrenia management. 

To comprehensively review the advancements in drug 

delivery systems for schizophrenia treatment, a 

systematic literature search was conducted using 

electronic databases such as PubMed, Scopus, and 

Web of Science. Keywords related to schizophrenia, 

drug delivery systems, targeted therapy, nanoparticle-

based formulations, lipid-based carriers, depot 

injections, transdermal patches, implantable devices, 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 04-2024 4 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 04 PAGES: 1-7 

SJIF IMPACT FACTOR (2022: 5. 705) (2023: 6.534) (2024: 7.7) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

and nanoscale drug carriers were used to identify 

relevant articles published within the past decade. 

  

 

 

In addition to primary research articles, review papers 

and book chapters were consulted to gather insights 

into the underlying principles and mechanisms of 

various drug delivery strategies. Emphasis was placed 

on understanding how each delivery system addresses 

the unique challenges associated with schizophrenia 

treatment, such as poor oral bioavailability, blood-

brain barrier penetration, and medication non-

adherence. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 04-2024 5 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 04 PAGES: 1-7 

SJIF IMPACT FACTOR (2022: 5. 705) (2023: 6.534) (2024: 7.7) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

Furthermore, studies evaluating the comparative 

effectiveness and tolerability of different drug delivery 

systems were critically appraised to identify trends, 

knowledge gaps, and areas for future research. Special 

attention was given to emerging technologies and 

novel formulations that have the potential to 

revolutionize schizophrenia treatment by improving 

therapeutic outcomes and patient adherence. 

By employing a multidisciplinary approach that 

integrated findings from pharmacology, 

pharmaceutics, neuroscience, and clinical psychiatry, 

this review aimed to provide a comprehensive 

overview of the advancements in drug delivery 

systems for schizophrenia treatment. Through a critical 

synthesis of existing literature, this study aimed to 

inform researchers, clinicians, and pharmaceutical 

developers about the opportunities and challenges in 

the development and implementation of targeted 

therapy approaches for schizophrenia. 

RESULTS 

The review of advancements in drug delivery systems 

for schizophrenia treatment highlights several 

promising strategies aimed at overcoming the 

limitations of conventional pharmacotherapy. 

Nanoparticle-based formulations have shown 

potential for enhancing drug bioavailability and blood-

brain barrier penetration, thereby improving the 

delivery of antipsychotic medications to the central 

nervous system. Lipid-based carriers offer advantages 

in terms of sustained release and enhanced drug 

stability, while depot injections provide a convenient 

and long-acting alternative to oral medications, 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 04-2024 6 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 04 PAGES: 1-7 

SJIF IMPACT FACTOR (2022: 5. 705) (2023: 6.534) (2024: 7.7) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

improving treatment adherence. Transdermal patches 

and implantable devices offer non-invasive and 

controlled delivery of antipsychotic drugs, further 

enhancing patient compliance and therapeutic 

efficacy. Additionally, nanoscale drug carriers hold 

promise for targeted drug delivery and precise control 

over drug release kinetics, offering opportunities for 

personalized treatment approaches. 

DISCUSSION 

The discussion focuses on the implications of these 

advancements in drug delivery systems for 

schizophrenia treatment. The targeted delivery of 

antipsychotic medications to the brain holds the 

potential to improve therapeutic outcomes by 

maximizing drug efficacy while minimizing systemic 

side effects. Moreover, the development of long-

acting formulations and novel delivery modalities has 

the potential to address the challenge of poor 

treatment adherence, a common barrier to effective 

schizophrenia management. By enhancing drug 

stability, bioavailability, and patient compliance, these 

drug delivery systems offer new avenues for 

optimizing schizophrenia treatment and improving 

patient outcomes. 

CONCLUSION 

In conclusion, the advancements in drug delivery 

systems represent a promising frontier in 

schizophrenia treatment. Through targeted therapy 

approaches, these systems offer the potential to 

overcome the limitations of conventional 

pharmacotherapy and improve therapeutic outcomes 

for individuals living with schizophrenia. By enhancing 

drug delivery to the brain, prolonging drug action, and 

improving treatment adherence, these systems hold 

the promise of transforming schizophrenia 

management and enhancing the quality of life for 

patients. Moving forward, continued research and 

development in this area are essential to realizing the 

full potential of targeted therapy in schizophrenia 

treatment and improving the lives of individuals 

affected by this complex psychiatric disorder. 

REFERENCES 

1. Schizophrenia  spectrum  and  other  psychotic 

disorders. In: Diagnostic and Statistical Manual of  

Mental  Disorders  DSM-5.  5th  ed.  Arlington,  Va.: 

American Psychiatric Association; 2013. 

2. 2. Xiberas  X,  Martinot  JL,  Mallet  L,  Artiges  E,  

Canal M, Loc’h C, Maziere B, Paillère-Martinot ML:   

In   vivo   extrastriatal   and   striatal   D2   dopamine 

receptor blockade by amisulpride in schizophrenia.      

J      Clin      Psychopharmacol      2001;21:207–214. 

3. 3. Boyer  P,  Lecrubier  Y,  Puech  A  J,  Dewailly  J,  

Aubin  F.  Treatment  of  negative  symptoms  in  

schizophrenia      with      amisulpride.      Br      J      

Psychiatry. 1997;166: 68–72. 

4. 4. International   1.   Sarker   DK,   Engineering   of   

nanoemulsion  for  drug  delivery,  Current  Drug  

Delivery, 2005;(2): 297-310. 

5. 5. Sole, I., Maestro A., Gonzalez C., Solans C. and 

Gutierrez J. M. Optimization of Nano-emulsion 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 04-2024 7 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 04 PAGES: 1-7 

SJIF IMPACT FACTOR (2022: 5. 705) (2023: 6.534) (2024: 7.7) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

Preparation   by   Low-Energy   Methods   in   an   

Ionic  Surfactant  System.  Langmuir,  2006;  vol.  22, 

8326-8332. 

6. 6. Chhabra  G,  Chuttani  K,  Mishra  AK,  Pathak  K.  

Design   and   development   of   nanoemulsion   

drug delivery system of amlodipine besilate for 

improvement  of  oral  bioavailability.  Drug  Dev  

Ind pharm. 2011;37(8): 907-16. 

7. 7. Bouchemal  K,  Briançon  S,  Perrier  E,  Fessi  H.  

Nano-emulsion formulation using spontaneous 

emulsification:    solvent,    oil    and    surfactant    

optimisation       International       Journal       of              

Pharmaceutics. 2004; 280:241–251. 

8. 8. Sheikh S, Faiyaz S, Sushma T, Farhan J, Roop K, 

Khar   MA.   Development   and   bioavailability 

assessment       of       ramipril       nanoemulsion       

formulation.         European         Journal         of         

Pharmaceutics   and   Biopharmaceutics.   2007;   66: 

227–243. 

9. 9. Kentish,  S.;  Wooster,  T.;  Ashok  kumar,  M.;  

Balachandran,  S.;  Mawson,  R.;  Simons,  L.  The  

use      of      ultrasonics      for      nanoemulsion      

preparation.  Innovat.  Food  Sci.  Emerg.  Tech.  

2008; 9, 170-175. 

10. 10. Jafari,  S.;  He,  Y.;  Bhandari,  B.  Nano-emulsion 

production      by      sonication      and      micro-

fluidization-  a  comparison.  Int.  J.  Food  Prop.  

2006; 9, 475-485. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=

